BACKGROUND: There is no standard treatment for patients with advanced colorectal cancer (CRC) progressing after irinotecan and oxaliplatin treatment and having good performance status (PS). PATIENTS AND METHODS: We investigated gemcitabine 1,000 mg/m2 days 1, 8 and 15 q28d combined with protracted 5-fluorouracil continuous infusion at 200 mg/m2/day, in 37 consecutive patients progressing after oxaliplatin-irinotecan-containing chemotherapies. RESULTS: Partial response (PR) was achieved in 4 (10.8%) and disease stabilization (SD) in 19 (51.4%) cases (PR+SD: 62.2%). Median time to progression and survival were 4.2 and 8.9 months, respectively. Grade III toxicities were thrombocytopenia, neutropenia (in 3 patients) and mucositis (in 2 patients). Clinical benefit was observed in 18 patients (48.6% of the entire population; 64.3% of those patients with PS>0 at study entry). CONCLUSION: The combination of gemcitabine and 5-fluorouracil continuous infusion was found to be an active and manageable palliative regimen for heavily pre-treated patients with metastatic CRC.
BACKGROUND: There is no standard treatment for patients with advanced colorectal cancer (CRC) progressing after irinotecan and oxaliplatin treatment and having good performance status (PS). PATIENTS AND METHODS: We investigated gemcitabine 1,000 mg/m2 days 1, 8 and 15 q28d combined with protracted 5-fluorouracil continuous infusion at 200 mg/m2/day, in 37 consecutive patients progressing after oxaliplatin-irinotecan-containing chemotherapies. RESULTS: Partial response (PR) was achieved in 4 (10.8%) and disease stabilization (SD) in 19 (51.4%) cases (PR+SD: 62.2%). Median time to progression and survival were 4.2 and 8.9 months, respectively. Grade III toxicities were thrombocytopenia, neutropenia (in 3 patients) and mucositis (in 2 patients). Clinical benefit was observed in 18 patients (48.6% of the entire population; 64.3% of those patients with PS>0 at study entry). CONCLUSION: The combination of gemcitabine and 5-fluorouracil continuous infusion was found to be an active and manageable palliative regimen for heavily pre-treated patients with metastatic CRC.
Authors: A Abajo; J Rodriguez; N Bitarte; R Zarate; V Boni; M Ponz; A Chopitea; E Bandres; J Garcia-Foncillas Journal: Br J Cancer Date: 2010-10-12 Impact factor: 7.640
Authors: P Jiménez-Fonseca; M P Solis; M Garrido; L Faez; D Rodriguez; A L Ruiz; M L Sanchez Lorenzo; E Uriol; M D Menendez; J M Viéitez Journal: Clin Transl Oncol Date: 2014-11-27 Impact factor: 3.405
Authors: Tessa J J de Bitter; Ragna L A van der Linden; Shannon van Vliet; Fieke Weren; Daoud Sie; Bauke Ylstra; Hans C van der Linden; Nikki Knijn; Marjolijn J L Ligtenberg; Rachel S van der Post; Femke Simmer; Iris D Nagtegaal Journal: Histopathology Date: 2019-07-18 Impact factor: 5.087
Authors: D Strumberg; M E Scheulen; B Schultheis; H Richly; A Frost; M Büchert; O Christensen; M Jeffers; R Heinig; O Boix; K Mross Journal: Br J Cancer Date: 2012-05-08 Impact factor: 7.640